A clinical trial of axitinib plus PF-04856884 or axitinib alone for patients with metastatic renal cancer who have already been treated with an anti-VEGF agent.
- Registry ID
- EUCTR2011-002190-33
- Source registry
- EUCTR
- Status
- Prematurely Ended
- Phase
- PHASE2
- Sponsor
- PFIZER, S.L.U.
- Start date
- 2012-02-02
- Completion date
- 2014-03-27
- Last update
- 2026-08-16
Conditions
- METASTATIC RENAL CELL CARCINOMA
Summary
Part I (not applicable in Spain): To confirm that the combination of PF-04856884 and AG-013736 is safe and tolerable at the doses to be used in Part II of the study. Part II: To document clinical activity of the combination of PF-04856884 and AG-013736 or AG-013736 alone as measured by PFS in adult patients with previously treated mRCC.
Locations
- , , Czechia
- , , Finland
- , , Germany
- , , UK
- , , Spain
- , , Italy
- , , Austria
View on source registry